文献速递骨质疏松与代谢性骨病创伤骨科

西班牙骨折联络服务中极高骨折风险患者的药物处方充分性:REFRA FLS-SEIOMM登记研究分析

Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry.
PubMed 文献 · Osteoporos Int · 2025-09-12

该回顾性多中心队列研究纳入西班牙16个骨折联络服务中年龄≥50岁且近一年内至少发生一次脆性骨折的患者,按高骨折风险与极高骨折风险分类并评估药物治疗与SEIOMM指南的一致性。7161例中1413例可分类,其中极高骨折风险占26.8%,药物治疗总体启动率为86.5%,第一年新发骨折率为5.9%。

要点

  • 1413例可分类患者中,极高骨折风险379例(26.8%),高骨折风险1034例(73.2%)。
  • 极高骨折风险组中位年龄76岁,高于高骨折风险组的72岁(p < 0.001)。
  • 药物治疗启动率为86.5%,极高骨折风险组更多使用唑来膦酸、地舒单抗等胃肠外治疗。

核心结论

  • 26.8%的患者被分类为极高骨折风险,治疗与SEIOMM指南部分一致,但在极高骨折风险患者中提高序贯骨合成代谢治疗的依从性至关重要,跌倒预防对减少骨折复发仍然关键。

研究设计与样本

  • 回顾性、多中心、基于人群的观察性队列研究,纳入西班牙16个骨折联络服务中年龄≥50岁且近一年内至少发生一次脆性骨折的患者。
  • 数据收集自2015年1月至2024年4月的病历,采集社会人口学信息、骨折特征、合并症、药物治疗和跌倒风险。
  • 7161例患者中,1413例有1年随访且基线数据足以分类为极高骨折风险或高骨折风险。

主要发现

  • 1413例可分类患者中,1034例(73.2%)为高骨折风险,379例(26.8%)为极高骨折风险。
  • 极高骨折风险组中位年龄76岁 vs 高骨折风险组72岁(p < 0.001)。
  • 86.5%的患者启动了药物治疗;高骨折风险组主要处方阿仑膦酸,极高骨折风险组更常用胃肠外治疗(唑来膦酸、地舒单抗)。
  • 第一年内84例(5.9%)发生新发骨折,2次及以上跌倒与后续骨折显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoanabolics. Fall prevention is pivotal in reducing new fractures. OBJECTIVE: To classify patients treated in 16 Fracture Liaison Services (FLS) in Spain according to high-risk fracture (HRF) and very high-risk fracture (VHRF) and evaluate the alignment of their pharmacological treatment with the Spanish Society for Bone and Mineral Metabolism Research (SEIOMM) guidelines. Additionally, we assessed the incidence of new fractures over a one-year follow-up period and analyzed associated risk factors. METHODS: This retrospective, multicenter, population-based observational cohort study included patients aged ≥ 50 years with at least one fragility fracture in the preceding year. Data were collected from medical records from January 2015 to April 2024, capturing sociodemographic information, fracture characteristics, comorbidities, pharmacological treatments, and fall risk. RESULTS: Of 7161 patients, 1413 had one year of follow-up and sufficient baseline data for classification as either VHRF or HRF. Among these, 1034 (73.2%) were classified as HRF and 379 (26.8%) as VHRF. The median age was significantly higher in the VHRF group (76 vs. 72 years in HRF; p < 0.001). Pharmacological treatment was initiated in 86.5% of patients. Alendronate was predominantly prescribed for the HRF group, while parenteral treatments (zoledronate, denosumab) were more common in the VHRF group. During the first year, 84 patients (5.9%) experienced a new fracture, with 2 or more falls significantly associated with these subsequent fractures. CONCLUSION: 26.8% of patients were classified as VHRF. Treatment partially aligned with SEIOMM guidelines, though improved adherence to sequential osteoanabolic treatment is essential in VHRF patients. Fall prevention remains critical to reducing fracture recurrence.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Montoya-Garcia MJ, Carbonell-Abella C, García MG, et al. Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry. Osteoporos Int. 2025. PMID: 40938378. doi:10.1007/s00198-025-07565-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。